Bristol-Myers Squibb Co. said the Japanese Ministry of Health, Labor, and Welfare has approved Opdivo (nivolumab) for unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
